In context
Rusfertide mimics the iron-regulatory hormone hepcidin. The phase 2 REVIVE trial investigated control of excess red-cell production in people with phlebotomy-dependent polycythaemia vera. [1]
At a glance
- Type
- Peptide / related clinical research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- Iron regulation in a defined blood disorder is not a general energy or performance intervention. Study endpoints and the randomised-withdrawal design matter.
How to interpret this evidence
Iron regulation in a defined blood disorder is not a general energy or performance intervention. Study endpoints and the randomised-withdrawal design matter. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. pubmed.ncbi.nlm.nih.gov